🏛️ Verified NIH Record • Updated 2026-08-26
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) (NCT05490446)
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Agios Pharmaceuticals, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.
Who can join: Review the eligibility criteria below.
Location: Innovative Clinical Research Institute Whittier — Lakewood, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (45 Sites)
Showing the first 25 of 45 sites.
- Innovative Clinical Research Institute Whittier — Lakewood, California
- David Geffen School of Medicine at UCLA — Los Angeles, California
- Emad Ibrahim, MD, Inc. — Redlands, California
- Smilow Cancer Hospital at Yale New Haven — New Haven, Connecticut
- Mayo Clinic Jacksonville - PPDS — Jacksonville, Florida
- Edward H. Kaplan MD & Associates — Skokie, Illinois
- Washington University School of Medicine — St Louis, Missouri
- Memorial Sloan Kettering Cancer Center — Long Island City, New York
- Duke Adult Blood and Marrow Clinic — Durham, North Carolina
- Monash Health, Monash Medical Centre — Clayton, Victoria
- Ordensklinikum Linz GmbH Elisabethinen — Linz, Upper Austria
- Fakultni nemocnice Ostrava — Ostrava,
- Hôpital de La Conception — Marseille, Bouches-du-Rhône
- CHU Angers — Angers, Maine-et-Loire
- CHRU Lille — Lille,
- Hôpital Saint Louis — Paris,
- Medizinische Hochschule Hannover — Hanover, Lower Saxony
- Universitatsklinikum Dusseldorf — Düsseldorf, North Rhine-Westphalia
- Universitatsklinikum Leipzig — Leipzig, Saxony
- University Hospital of Alexandroupolis — Alexandroupoli,
- Attikon University General Hospital — Athens,
- University General Hospital of Patras — Pátrai,
- Hippokration Hospital — Thessaloniki,
- Shaare Zedek Medical Center — Jerusalem,
- Tel Aviv Sourasky Medical Center PPDS — Tel Aviv,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myelodysplastic Syndromes
- ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions — Clovis, California
- Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA — Tampa, Florida
- Inqovi Maintenance Therapy in Myeloid Neoplasms — Boston, Massachusetts
- Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) — Birmingham, Alabama
- CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome — Tampa, Florida
Explore by condition: All Myelodysplastic Syndromes clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.